Cabazitaxel bulk supplier for pharma manufacturers

Cabazitaxel 60 mg/1.5 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 60 mg/1.5 mL

Reference Brands: Jevtana®(US & EU)

Cabazitaxel is an oncology drug used for advanced prostate cancer (mCRPC). Available as a 60 mg/1.5 mL injection in the US and EU under the brand Jevtana®.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Cabazitaxel? List it or send an offer →

Product Description: Cabazitaxel, a next-generation taxane chemotherapy agent, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients previously treated with docetaxel. Marketed under the brand Jevtana® in the US and EU, it is available as a 60 mg/1.5 mL injectable concentrate, requiring dilution before intravenous infusion. Cabazitaxel inhibits microtubule depolymerization, disrupting cancer cell mitosis. Manufactured under strict GMP standards, Cabazitaxel is a key product for B2B pharma partners focused on oncology and urology segments. It presents reliable commercial opportunities in highly regulated markets across Europe and North America.

Cabazitaxel — third party manufacturing & bulk supply

Cabazitaxel 60 mg/1.5 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Cabazitaxel is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Cabazitaxel listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Cabazitaxel →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Cabazitaxel is listed as Injection in 60 mg/1.5 mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Cabazitaxel is referenced against Jevtana®(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.